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Sinary Non-small-cell lung cancer (NSCLC) prognosis is stnrctly related to well-established
clinicopathological parameters which have unfortunately become insufficient in the prognostic evaluation of
this type of cancer. As p53 and bcl-2 gene deregulations are frequently involved in several types of epithelial
malignancies, we investigated the Bcl-2 and p53 protein expression in 91 and 101 cases of NSCLC respectively.
The expression was then compared with established indicators of prognosis and biological behaviour of the
tumours. No relationship was observed between Bcl-2 and either clinicopathological or biological parameters
such as histology, grading, tumour status, nodal metastasis and proliferative activity evaluated by scoring
proliferating cell nuclear antigen expression and Ki-67 immunoreactivity. However, the mean Bcl-2 expression
was significantly lower in patients who developed metastasis during follow-up or died of metastatic disease
(P = 0.006 and P= 0.01 respectively). Moreover, survival probability was higher in patients who expressed the
Bcl-2 protein (P =0.0002). In contrast with this, p53 protein accumulation was observed in tumours with
metastatic nodal involvement (P = 0.02) or in patients who developed metastasis during follow-up (P = 0.01),
although no correlation was found between p53 expression and overall survival. An inverse relationship was
also found between Bcl-2 and the anti-oncogene protein product p53 (P = 0.01). Thus, a high proportion of
NSCLCs express p53 and Bcl-2 proteins and their expression may have prognostic importance.
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Lung cancer has now become the leading cause of cancer
deaths in both men and women in the USA (Minna et al.,
1989). In particular, non-small-cell lung cancer (NSCLC)
represents a heterogeneous subgroup in terms of both
behaviour and therapeutic response.
Several studies have clearly demonstrated that multiple
genetic events are associated with the development of lung
cancer, including a range of chromosomal abnormalities,
mutations activating the dominant cellular proto-oncogenes
and genetic events inactivating tumour suppressor genes
(Minna, 1993).
p53 alterations and aberrant nuclear accumulation of this
protein have been recently studied with particular interest.
Many experimental data indicate that the p53-suppressor
gene is the most commonly altered tumour-suppressor gene
(Hollstein et al., 1991). This gene codes for a nuclear phos-
phoprotein, normally undetectable in human cells, which is
able to regulate cell growth and division (Levine et al., 1991;
Lane, 1992). p53 protein may be detected by immunocyto-
chemistry in cancer cells as a consequence either ofmutational
events in p53 gene or of stabilisation by other factors such as
some viral proteins. p53 alterations appear early during
NSCLC progression; these alterations are maintained during
invasion and metastatic spread ofcancer cells (Quinlan et al.,
1992; Fontanini et al., 1994), inducing a proliferative advan-
tage and conferring a particularly aggressive phenotype.
The bcl-2 gene was originally discovered owing to its
involvement in the t(14;18) chromosomal translocation
occurring in the majority of non-Hodgkin's B-cell lym-
phomas (Tsujimoto and Croce, 1986; Aisemberg et al., 1988).
This translocation places the bcl-2 gene at chromosomal
location 18q21 in juxtaposition with the immunoglobulin
heavy-chain locus at 14q32, resulting in transcriptional
deregulation of the bcl-2 gene (Cleary et al., 1984; Tsujimoto
and Croce, 1986; Tsujimoto et al., 1987) and abnormally
high levels of the Bcl-2 protein. Furthermore, overexpression
of the Bcl-2 protein has been observed in different types of
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solid tumours, including prostate (Colombel et al., 1993),
lung (Pezzella et al., 1993a), thyroid (Pilotti et al., 1994) and
breast (Silvestrini et al., 1994). In contrast with lymphomas,
little or no evidence of gross alterations in the bcl-2 gene
structure was obtained for these other types of cancer, sug-
gesting that alternative mechanisms of deregulation of Bcl-2
expression may exist in human cancer (Leek et al., 1994).
The high incidence of p53 alterations and the aberrant
expression of Bcl-2 in many human cancers together with
their putative prognostic significance in lung (Pezzella et al.,
1993a) and breast cancer (Silvestrini et al., 1994) induced us
to study the p53 and Bcl-2 expression in a series ofNSCLCs,
with particular regard to their relationship, according to
metastatic assessment and overall survival.
Materials and methods
Patients and tissue samples
The study involved 101 patients with primary resectable non-
small-cell lung cancer. The patients (91 men and ten women,
mean age 63 ± 6.4 years) presented no clinical or radiological
evidence of distant metastases at diagnosis and underwent
lobectomy or pneumonectomy between March 1991 and
December 1992 at Santa Chiara Hospital of Pisa University.
The median follow-up was 25 months (range 2-41). The
histopathological features of the surgical specimens were
classified and staged according to the World Health
Organization (1982) criteria and the TNM staging system
(Mountain, 1987). Immediately after surgery a part of the
tumour sample was processed by conventional histological
procedures for the determination of the Bcl-2 and prolifera-
tion cell nuclear antigen (PCNA) expression. The rest of the
tumour material was frozen in liquid nitrogen and stored at
- 80'C for p53 and Ki-67 determination.
Immnohistochemistry
A total of 101 and 91 samples were examined for p53 and
Bcl-2 expression respectively. In 90 cases both p53 and Bcl-2
immunoreactions were performed.Bc-2 and p53 h N r
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Bcl-2 inmunostaining The 5 iLm tumour sections were
immunostained using the alkaline phosphatase-anti-alkaline
phosphatase (APAAP) method (Cordell et al., 1984) with the
anti-Bcl-2 monoclonal antibody (clone 124) (Pezzella et al.,
1992) raised to a synthetic peptide. Briefly, paraffin sections
were dewaxed in xylene and dehydrated through graded
alcohols. The monoclonal antibody Bcl-2 124 was applied
overnight at 1:20 dilution. A rabbit anti-mouse secondary
antibody prediluted in 0.05 M Tris buffer containing normal
swine serum was applied for half an hour. The alkaline
phosphatase-mouse anti-alkaline phosphatase immune com-
plex was applied for half an hour first and then for 10 mi;
during the interval the anti-mouse serum was used. The
reaction was developed with alkaline phosphatase substrate
containing naphthol AS-MX fast red Tr and levamisole
(APAAP Kits, Dako). As a positive control for Bcl-2, we
used a paraffin-embedded section from a normal peribron-
chial lymph node removed during post-surgical sampling of a
lung tumour. At the same time positive staining of small
lymphocytes provided an internal control for Bcl-2 staining.
Staining without anti-Bcl-2 monoclonal antibody was per-
formed as a negative control procedure. The Bcl-2
immunoreactivity was assessed by scoring a minimum of five
high-power fields (HPFs) (40 x objective lens).
p53 immunostaining
For p53 detection the anti-p53 monoclonal antibody PAb
1801 (Oncogene Science, Manhasset, NY, USA) was used
overnight at 1:200 dilution on 5 Lm frozen sections, as
previously reported (Fontanini et al., 1993a). This antibody
reacts specifically with human wild-type and mutant p53
recognising an N-terminal epitope of the protein. The
avidin-biotin-peroxidase method was used, developing the
immunoreaction with diaminobenzidine. Simultaneous stain-
ing of a known p53+ case was employed as a positive control
for p53 expression. Incubation of parallel slides omitting the
first antibody was performed as the negative control. As for
Bcl-2, the number of p53-immunoreactive cells was counted
by sconrng a minimum of five HPFs (40 x objective lens).
PCNA and Ki-67 score
Proliferative activity in each sample was evaluated using
PCIO and Ki-67 MAbs on paraffin-embedded and frozen
sections respectively, as previously reported (Fontanini et al.,
1993b). Absolute counts of PCIO and Ki-67 immunoreac-
tivity were made by scoring a minimum of five HPFs
(40 x objective lens); 1% PC10- and Ki-67-positive tumour
cells out of the total number of tumour cells counted pro-
vided the PCNA and Ki-67 index for each tumour.
Statistical analysis
All statistical analyses were carried out by the STATISTICA
(Stat-Soft) software system. The differences between p53 and
Bcl-2 expression and clinicopathological parameters were
assessed by the unpaired t-test. The relationship between the
p53 and Bcl-2 expression was evaluated by a chi-square test
and by a linear regression coefficient test. Survival analysis
was calculated bv the Kaplan-Meier method.
Results
Bcl-2 protein immunostaining
Bcl-2 immunoreactivity was localised in the cytoplasm of
neoplastic cells (Figure la); no nuclear Bcl-2 positivity was
found in this series of cancers. We evaluated as positive
tumours with only 1% of stained cells, provided this
positivity was very defined and localised in the cytoplasm of
neoplastic cells. Heterogeneous staining was sometimes
detected in the basal layer cells of the normal bronchial
epithelium adjacent to tumour areas. The frequency of cells
a
b
Figwe 1 (a) Bcl-2 expression in the cytoplasm of tumour cells
(anti-Bcl-2 MAAb, APAAP method, 25 x). (b) p53 nuclear
immunoreactivity detected in neoplastic cells using PAb 1801
(ABC method, 25 x).
expressing the Bcl-2 protein varied widely from one tumour
to the other. Bcl-2 protein immunopositivity was detected in
61 out of the 91 (67%) tumour samples examined, ranging
from 1.5% to 90% positive cells (mean 27.1 + 25.1; median
15).
Bcl-2 expression and clinicopathological parameters As
reported in Table I, no statistical differences in Bcl-2 expres-
sion were found between: (1) tumour histotype, (2) tumour
grade, (3) tumour status and (4) nodal metastasis.
Bcl-2 expression and proliferative activity Highly pro-
liferating tumours (cut-off 30% for PCNA and 13% for
Ki-67) express a percentage of positive cells similar to that of
tumours with low proliferative activity (Table II). These
results suggest that the Bcl-2 protein expression is indepen-
dent of the proliferative status of the tumours.
Bcl-2 expression in relation to distant metastasis and sur-
vival In 89 out of 91 patients the data regarding develop-
ment of metastases and overall survival were available (two
patients died during the post-operative period). In order to
determine whether the alterations in the Bcl-2 protein may be
a prognostic indicator in NSCLC, we analysed Bcl-2 expres-
sion both in tumours from patients with and without metas-
tases and in patients still alive or dead from neoplastic
disease. Bcl-2 expression was significantly higher (P<0.006)
in tumours from metastasis-free patients than in tumours
from patients with distant metastases. We also found that
tumours from living patients presented a higher number of
Bcl-2-immunoreactive cells than tumours from dead patients
(P<0.01) (Table III). The same results obtained from sur-
vival analysis are reported in Figure 2a. NSCLC patients
with Bcl-2-positive tumours had a higher probability of sur-
vival than patients with Bcl-2-negative cancers (Kaplan-
Meier analysis, P= 0.0002). We obtained the same resultsTable I Clinicopathological data and immunocytochemical
reactivity for Bcl-2 protein in 91 cases of NSCLC
Bcl-2 inmunoreactivity
Variables No. of cases Mean (±s.d.) P
Sex
Male 81 17.6 23.7 NS
Female 10 22.9 28.8
Histology
Squamous 55 19.9 ± 23.2 NS
Non-squamous 36 15.4 ± 26.6
Grading
GI 16 17.7±24.4
G2 38 18.1±23.5 NS
G3 37 17.1 251
T-status
TI 16 22.8 23.8
T2 64 17.4 24.2 NS
T3 11 15.7 25.7
N-status
NO 64 17.5 21.8 NS
Ni-2 27 19.6 29.4
aUnpaired t-test.
Table H Bcl-2 protein expression in NSCLC according to PCNA
and Ki-67 immunoreactivity
Proliferative Bel-2 immoreactivity
activity No. of cases Mean ( s.d) P
PCNA
< 30a 33 15.3 25.9 0.6
>30 26 18.1 26.5
Ki-67
<13a 35 17.6±27.8
>13 24 15.6±24.7 0.6
aUfnpaired t-test.
Tabe m Relationship between Bcl-2 protein expression, survival
and metastasis in 89 patients with NSCLC
Bcl-2 expression
No. of cases Mean (±s.d) P
Alive 51 22.8 24.2 0.01
Dead 38 10.8 ± 22.3
No metastasis 48 24.2 ± 24.4
Metastasis 41 10.2 21.5
'Unpaired t-test.
when considering Bcl-2 expression as a dichotomous variable
(negative vs positive tumours) (Table IV). Taken together,
these results suggest that Bcl-2 expression may be considered
as a favourable prognostic marker in this type of cancer.
p53protein immunostaining
p53 immunostaining was performed in 101 cases. Sixty-nine
cases were found to be positive and 32 negative (mean
39.9 + 28.5; range 1-85). Immunoreactivity was confined to
the nuclei of neoplastic cells (Figure lb) with the following
staining pattern: (a) tumours with only a few scattered
positive cells (< I%) or none at all were considered negative;
tumours with more than 1% positive cells with either (b)
heterogeneous or (c) homogeneous distribution were
evaluated as positive.
p53 expression and cliicopathological parameters The mean
p53 immunoreactivity according to clinicopathological
parameters is summarised in Table V. As is shown, no
correlation was found between p53 expression and
clinicopathological parameters such as T status, histiotype
and tumour grade. By contrast, mean p53 immunoreactivity
Bd-2 an p53 in N=C $pm
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Fwe 2 Survival of patients with non-small-cell lung cancer
according to status of Bcl-2. (a) and p53 (b) proteins (Kap-
lan-Meier method).
Table IV Survival and metastasis in 89 patients with NSCLC
according to Bcl-2 expression
Bcl-2 expression
Positie casesl Negative cases/ P
total total
Alive 42 9 0.0005
Dead 17 21
No metastasis 40 8
Metastasis 19 22 0.0006
aContingency tables.
Table V p53 immunoreactivity in 101 cases ofNSCLC according to
cinicopathological parameters
p53 imunoreactivity
Variables No. of cases Mean (+s.d) P
Sex
Male 91 27.9 ± 27.6 NS
Female 10 21.1 33.3
Histology
Squamous 64 24.7 27.4 NS
Non-squamous 37 31.6 29.2
Grading
GI 17 24.7±28.9
G2 43 26.1 27.7 NS
G3 41 31.1 28.7
T-status
Ti 17 25.4±30.6
T2 73 27.7 27.4 NS
T3 11 22.04±31.8
N-status
NO 62 22.9 26.6 002
NI -2 39 36.6+ 29.4
aUnpaired i-test.
in tumours from patients with hilar and/or mediastinal nodal
involvement was significantly higher than in patients without
nodal metastasis (P = 0.02).
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Tabek VI p53 expression in NSCLC according to the development
of metastasis and survival
p53 immunoreactivity
No. of cases Mean (± s.d) P
Metastasis 44 35.4 28.3
No metastasis 55 21.7 26.7 0.01
aUnpaired t-test.
Table VII Bcl-2 and p53 expression in 59 cases of non-small cell
lung cancer
Bcl-2 expression
No. ofpositive No. of negative
pS3 expression cases/Total % cases/Total % P
p53 positive 36 60 26 86.7
p53 negative 24 40 4 13.3 0.01
aContingency tables.
p53 expression in relation to distant metastases and survival
In 99 out of 101 cases we obtained data concerning either the
development of metastases during follow-up or overall sur-
vival (two patients died during the post-operative period).
Forty-four out of 99 (44.4%) patients who had developed
distant metastasis showed a higher mean p53 positivity
(35.4%) than metastasis-free patients (21.7%) (P = 0.01;
Table VI). On the other hand, overall survival was not
affected by p53 overexpression (Figure 2b; Kaplan-Meier
method).
Bcl-2 andp53protein expression
Staining for both Bcl-2 and p53 was available in 90 cases.
The results are summarised in Table VII. Of60 Bcl-2-positive
tumours, 60% showed p53 overexpression, whereas of 30
Bcl-2-negative tumours 87% showed p53 immunoreactivity
(P= 0.01). Regression analysis is reported in Figure 3; a
clear inverse correlation was found between the p53 and
Bcl-2 protein expression (P = 0.01).
Bcl-2 and p53 proteins are both related to programmed cell
death or apoptosis and thus their relationship is of interest.
In this series of NSCLCs the results showed that Bcl-2 and
p53: (a) are detectable by the immunohistochemical techni-
que in about 60% and 70% of cases respectively; (b) are
inversely associated; and (c) provide information regarding
metastasis onset and overall survival probability.
Bcl-2 represents the product of the proto-oncogene
involved in the 14;18 translocation; its distribution in reactive
lymph nodes and lymphomas has already been described
(Villeundas et al., 1992; Pezzella et al., 1993b; Piris et al.,
1994). Bcl-2 expression has been observed not only in the
B-lymphoma but also in different types ofsolid tumours such
as breast (Leek et al., 1994; Silvestrini et al., 1994), prostate
(Colombel et al., 1993) thyroid (Pilotti et al., 1994) and lung
cancer (Pezzella et al., 1993a).
In particular, in NSCLCs, which are believed to orginate
from the respiratory epithelium, Bcl-2 overexpression was
related with better overall survival (Pezzella et al., 1993a).
Our results obtained from a group of 91 NSCLC patients
with median follow-up of 24 months agree with those
reported by Pezzella et al. However, both studies found that
Bcl-2 overexpression seems to be able to induce a less aggres-
sive tumour phenotype. The reason for this remains to be
clarified. Interestingly, in other types of cancers such as
breast (Leek et al., 1994; Silvestrini et al., 1994), thyroid
(Pilotti et al., 1994) and prostate (Colombel et al., 1994) a
strong association has been found between Bcl-2 expression
and tumour differentiation, suggesti that this gene may
somehow act to switch off proliferation during tumour pro-
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Fugwe 3 Relation between Bcl-2 and p53 expression in 90 cases
of non-snmll-cenl lung cancer (linear regression coefficient test).
gression. However, this hypothesis cannot be confirmed in
lung cancer since we failed to find any differences in the Bcl-2
expression of tumours of different grade. It is known that
Bcl-2 promotes cell survival even when the cell proliferation
rate is not elevated. This could provide a growth advantage
eventually leading to neoplastic transformation (Vaux et al.,
1988). McDonnel et al. (1989) suggested that for cellular
clones in which a low proliferative rate is offset by Bcl-2
expression the acquisition rate of complementary defects is
slower than in clones with a higher proliferative rate.
The association of a growth advantage owing to cellular
survival with low proliferative rate and slower acquisition of
further genetic defects could explain the slow evolution of
follicular lymphoma in which Bcl-2 expression is a frequent
primary aberration (Vaux et al., 1988; McDonnel et a!.,
1989). Different authors have suggested recently that altera-
tions in Bcl-2 could be present as a frequent aberration not
only in follicular lymphoma (Korsmeyer, 1992), but also in
other types of cancer such as breast (Silvestrini et al., 1994;
Leek et al., 1994) and lung (Pezzella et al., 1993a) car-
cinomas. This relation could be responsible for the increasing
likelihood ofmutational aberrations in other oncogenes, such
as those interfering with growth and proliferation of tumour
cells.
Our observations of a subgroup of patients with slowly
progressing Bcl-2-positive tumours suggest that in these
tumours Bcl-2 expression is likely to occur as an initial
alteration kading to a less aggressive behaviour of tumours.
This is in agreement with the inverse relationship between
Bcl-2 and p53 which we found in our series of cancers,
supporting the hypothesis that either one or the other is
sufficient to modify the apoptotic pathway in NSCLC.
In our study Bcl-2 expression is not associated with cell
proliferation evaluated as a percentage of PC1O- or Ki-67-
immunoreactive cells. In addition, we found that the bron-
chial epithelium expresses Bcl-2 in a proportion ofbasal cells,
and that there is a total lack of Bcl-2-positive cells in the
upper differentiated layers of the epithelium although hyper-
plasia is sometimes present in these areas. These findings
have been confirmed by Lu et al. (1993), who have recently
reported the lack of Bcl-2 expression in non-proliferating
syncytiotrophoblast and in psorasis despite evident mitoti
activity. This suggests that Bcl-2 is mainly associated with
activated and undifferentiated cells undergoing terminal
differentiation which need protection from apoptosis.
p53 is now well characterised as a tumour-suppressor gene,
with loss of normal p53 function recorded as the most com-
mon genetic event associated with human malignancies (Holl-
stein, 1991). p53 alterations with consequent aberrant nuclear
accumulation have been correlated with progression and
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poor prognosis in some solid tumours such as breast (Thor et
al., 1992; Allred et al., 1993; Silvestrini et al., 1993), gastric
(Martin et al., 1992), bladder (Sarkis et al., 1993) and lung
(Quinlan et al., 1992) carcinomas. In a series of 103 NSCLCs
(Fontanini et al., 1993a) we found that p53 protein overex-
pression correlated with metastatic involvement of hilar and/
or mediastinal lymph nodes, supporting other findings by
Quinlan et al. about the negative prognostic role of p53
alterations in NSCLC. In this group of patients it was
confirmed that p53 accumulation may predict the metastatic
behaviour of NSCLC, and that it is overexpressed not only
in cancer with nodal metastatic involvement at diagnosis but
also in tumours which develop distant metastases during
follow-up.
Our present results indicate on the one hand an inverse
relationship between Bcl-2 and p53 expression and, on the
other hand, an inverse prognostic significance of these
variables in NSCLC behaviour. The loss of Bcl-2 expression
is in fact associated with shorter overall survival, metastatic
development during follow-up and other poor prognostic
markers such as p53 positivity. For this reason, the role of
Bcl-2 in lung cancer progression may differ from that seen in
lymphomas in which the translation 14;18 occurs.
Further efforts are needed to assess the prognostic
significance of Bcl-2 and its relation with other gene products
involved in the regulation of apoptosis and proliferation.
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